

# Peripheral Neuropathy Therapeutic and Drug Pipeline Review H2

*Peripheral Neuropathy Treatment Pipeline Review H2 2016*

PUNE, INDIA, January 23, 2017

/EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for [Peripheral Neuropathy](#) (Sensory Neuropathy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and features dormant and discontinued projects.



WISE GUY  
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/619286-peripheral-neuropathy-sensory-neuropathy-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

## Scope

- The report provides a snapshot of the global therapeutic landscape of Peripheral Neuropathy (Sensory Neuropathy)

- The report reviews pipeline therapeutics for Peripheral Neuropathy (Sensory Neuropathy) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Peripheral Neuropathy (Sensory Neuropathy) therapeutics and enlists all their major and minor projects
- The report assesses Peripheral Neuropathy (Sensory Neuropathy) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Peripheral Neuropathy (Sensory Neuropathy)

#### Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peripheral Neuropathy (Sensory Neuropathy) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

#### Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Peripheral Neuropathy (Sensory Neuropathy) Overview 8

Therapeutics Development 9

Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Overview 9

Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis 10

Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Development by Companies 11

Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Investigation by Universities/Institutes 12

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Peripheral Neuropathy (Sensory Neuropathy) - Products under Development by Companies 16

Peripheral Neuropathy (Sensory Neuropathy) - Products under Investigation by Universities/Institutes 17

Peripheral Neuropathy (Sensory Neuropathy) - Companies Involved in Therapeutics Development 18

Araim Pharmaceuticals, Inc. 18

CSL Limited 19

GeNeuro SA 20

Mitsubishi Tanabe Pharma Corporation 21

Neuren Pharmaceuticals Limited 22

Pfizer Inc. 23

Pharnext SAS 24

Polyneuron Pharmaceuticals AG 25

RegeneRx Biopharmaceuticals, Inc. 26

Access Report @ <https://www.wiseguyreports.com/reports/619286-peripheral-neuropathy-sensory-neuropathy-pipeline-review-h2-2016> □

Get in touch:

LinkedIn: [www.linkedin.com/company/4828928](http://www.linkedin.com/company/4828928)

Twitter: <https://twitter.com/WiseGuyReports> □

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/363168673>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.